A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand

Despite the development of next-generation antiandrogens, metastatic castration-resistant prostate cancer (mCRPC) remains incurable. Here, we describe a unique semisynthetic bispecific antibody that uses site-specific unnatural amino acid conjugation to combine the potency of a T cell–recruiting ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sung Chang, Ma, Jennifer S. Y., Kim, Min Soo, Laborda, Eduardo, Choi, Sei-Hyun, Hampton, Eric N., Yun, Hwayoung, Nunez, Vanessa, Muldong, Michelle T., Wu, Christina N., Ma, Wenxue, Kulidjian, Anna A., Kane, Christopher J., Klyushnichenko, Vadim, Woods, Ashley K., Joseph, Sean B., Petrassi, Mike, Wisler, John, Li, Jing, Jamieson, Christina A. M., Schultz, Peter G., Kim, Chan Hyuk, Young, Travis S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357232/
https://www.ncbi.nlm.nih.gov/pubmed/34380625
http://dx.doi.org/10.1126/sciadv.abi8193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357232/
https://www.ncbi.nlm.nih.gov/pubmed/34380625
http://dx.doi.org/10.1126/sciadv.abi8193

Ejemplares similares